NASDAQ · LFCR
Healthcare · Drug Manufacturers - Specialty & Generic
$6.45
Down-$0.01 (-0.16%)
Updated Oct 7, 2026, 10:55 PM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · LFCR
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
LFCR closed at $6.45 after 21 trading sessions, up 49.65% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $6.51 | $6.54 | $6.44 | $6.45 | 1.23M |
| Oct 5, 2026 | $6.54 | $6.565 | $6.51 | $6.52 | 840.59K |
| Oct 2, 2026 | $6.55 | $6.55 | $6.53 | $6.54 | 504.72K |
| Oct 1, 2026 | $6.57 | $6.58 | $6.53 | $6.53 | 707.1K |
| Sep 30, 2026 | $6.55 | $6.61 | $6.54 | $6.58 | 970.23K |
| Sep 29, 2026 | $6.525 | $6.605 | $6.51 | $6.59 | 685.91K |
| Sep 28, 2026 | $6.52 | $6.6454 | $6.40 | $6.52 | 4.01M |
| Sep 25, 2026 | $4.27 | $4.39 | $4.1201 | $4.20 | 70.5K |
| Sep 24, 2026 | $4.41 | $4.41 | $4.21 | $4.29 | 97.24K |
| Sep 23, 2026 | $4.45 | $4.49 | $4.39 | $4.40 | 205.2K |
| Sep 22, 2026 | $4.52 | $4.52 | $4.3707 | $4.495 | 90.36K |
| Sep 21, 2026 | $4.48 | $4.51 | $4.215 | $4.48 | 170.71K |
| Sep 18, 2026 | $4.44 | $4.55 | $4.33 | $4.46 | 280.84K |
| Sep 17, 2026 | $4.22 | $4.48 | $4.16 | $4.46 | 144.71K |
| Sep 16, 2026 | $4.11 | $4.33 | $4.10 | $4.16 | 94.91K |
| Sep 15, 2026 | $4.21 | $4.225 | $4.13 | $4.14 | 76.09K |
| Sep 14, 2026 | $4.12 | $4.28 | $4.02 | $4.25 | 110.7K |
| Sep 11, 2026 | $4.14 | $4.185 | $4.06 | $4.12 | 159.52K |
| Sep 10, 2026 | $4.00 | $4.27 | $4.00 | $4.09 | 199.03K |
| Sep 9, 2026 | $4.29 | $4.31 | $4.03 | $4.09 | 264.99K |
| Sep 8, 2026 | $4.36 | $4.40 | $4.28 | $4.31 | 185.72K |
The latest Smart Investors Daily articles mentioning LFCR.
Company
Market Activity
Research & News
LFCR research
Company profile and research snapshot.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 29, 2026 | Barrington Research | Market Perform | — |
| Sep 28, 2026 | William Blair | Market Perform | — |
| Jun 16, 2026 | Barrington Research | Outperform | — |
| Apr 29, 2026 | Barrington Research | Outperform | — |
| Mar 27, 2026 | Barrington Research | Outperform | — |
No generated briefing is available yet.
Benzinga · Sep 29, 2026
https://www.sec.gov/Archives/edgar/data/1005286/000110465926111939/xslSCHEDULE_13D_X02/primary_doc.xml
Benzinga · Sep 29, 2026
Barrington Research analyst Michael Petusky downgrades Lifecore Biomedical (NASDAQ:LFCR) from Outperform to Market Perform.
SeekingAlpha · Sep 29, 2026
Lifecore Biomedical agreed to be acquired for $6.28/share in cash plus up to $3.39/share in CVRs. See why I rate LFCR stock a Hold right now.
Benzinga · Sep 28, 2026
William Blair analyst Max Smock downgrades Lifecore Biomedical (NASDAQ:LFCR) from Outperform to Market Perform.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LFCR.
